MX2009006315A - Compuesto heterociclico fusionado. - Google Patents

Compuesto heterociclico fusionado.

Info

Publication number
MX2009006315A
MX2009006315A MX2009006315A MX2009006315A MX2009006315A MX 2009006315 A MX2009006315 A MX 2009006315A MX 2009006315 A MX2009006315 A MX 2009006315A MX 2009006315 A MX2009006315 A MX 2009006315A MX 2009006315 A MX2009006315 A MX 2009006315A
Authority
MX
Mexico
Prior art keywords
optionally substituted
ring
atom
bonded
heterocyclic compound
Prior art date
Application number
MX2009006315A
Other languages
English (en)
Inventor
Tomoyasu Ishikawa
Hiroshi Banno
Youichi Kawakita
Tomohiro Ohashi
Osamu Kurasawa
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MX2009006315A publication Critical patent/MX2009006315A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se describe un compuesto heterocíclico fusionado que tiene actividad inhibidora de quinasa de tirosina. La fórmula (I) en la fórmula, R1 representa un átomo de hidrógeno, un átomo de halógeno, o un grupo opcionalmente sustituido el cual es unido a través de un átomo de carbono, un átomo de nitrógeno o un átomo de oxígeno, R2 representa un átomo de hidrógeno o un grupo opcionalmente sustituido el cual está unido a través de un átomo de carbono o un átomo de azufre, o como alternativa R1 y R2 o R2 y R3 son unidos respectivamente juntos para formar una estructura de anillo opcionalmente sustituido; R3 representa un átomo de hidrógeno o un grupo hidrocarburo alifático opcionalmente sustituido o alternativamente R2 está unido con un átomo de carbono del anillo A para formar una estructura de anillo opcionalmente sustituido; y el anillo A representa un anillo de benceno opcionalmente sustituido; y el anillo B representa (i) un anillo fusionado, o (u) un anillo de piridina que tiene un carbamoilo opcionalmente sustituido (en donde el anillo de piridina puede ser substituido en forma adicional).
MX2009006315A 2006-12-12 2007-12-11 Compuesto heterociclico fusionado. MX2009006315A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006335158 2006-12-12
PCT/JP2007/073879 WO2008072634A1 (ja) 2006-12-12 2007-12-11 縮合複素環化合物

Publications (1)

Publication Number Publication Date
MX2009006315A true MX2009006315A (es) 2009-10-13

Family

ID=39511655

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006315A MX2009006315A (es) 2006-12-12 2007-12-11 Compuesto heterociclico fusionado.

Country Status (13)

Country Link
US (1) US20100004238A1 (es)
EP (1) EP2103620A1 (es)
JP (1) JPWO2008072634A1 (es)
KR (1) KR20090090336A (es)
CN (1) CN101611041A (es)
AR (1) AR066962A1 (es)
BR (1) BRPI0720169A2 (es)
CA (1) CA2673097A1 (es)
MX (1) MX2009006315A (es)
PE (1) PE20091243A1 (es)
RU (1) RU2009126576A (es)
TW (1) TW200925160A (es)
WO (1) WO2008072634A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2009113560A1 (ja) * 2008-03-12 2011-07-21 武田薬品工業株式会社 縮合複素環化合物
RU2712220C2 (ru) * 2013-07-31 2020-01-27 Мерк Патент Гмбх Пиридины, пиримидины и пиразины в качестве ингибиторов тирозинкиназы брутона и их применение
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
ES2654931T3 (es) * 2013-12-26 2018-02-15 Ignyta, Inc. Derivados de pirazolo[1,5-a]piridina y procedimientos de uso de los mismos
CN104876941B (zh) * 2014-02-28 2019-02-01 南京汇诚制药有限公司 稠合三环类化合物及其应用
CN105085489B (zh) 2014-11-05 2019-03-01 益方生物科技（上海）有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
CN105924389A (zh) * 2015-12-18 2016-09-07 重庆两江药物研发中心有限公司 瑞戈非尼中间体的制备方法
CN105837453A (zh) * 2016-03-31 2016-08-10 常州大学 一种3,5-二氯-4’-硝基二苯醚的合成方法
WO2019214651A1 (zh) * 2018-05-08 2019-11-14 南京明德新药研发有限公司 作为选择性HER2抑制剂的吡咯并[2,1-f][1,2,4]三嗪类衍生物及其应用
RS65413B1 (sr) * 2018-09-18 2024-05-31 Hoffmann La Roche Derivati hinazolina kao antitumorski agensi
WO2021088987A1 (zh) * 2019-11-08 2021-05-14 南京明德新药研发有限公司 作为选择性her2抑制剂的盐型、晶型及其应用
KR20220110524A (ko) * 2019-12-04 2022-08-08 아르커스 바이오사이언시즈 인코포레이티드 Hif-2알파의 억제제
CN114671867B (zh) * 2022-03-15 2023-09-19 上海法默生物科技有限公司 妥卡替尼中间体7-羟基-[1,2,4]三唑并[1,5-a]吡啶的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
CA2223081C (en) 1995-06-07 2001-03-06 Pfizer Inc. Heterocyclic ring-fused pyrimidine derivatives
US6395733B1 (en) * 1995-06-07 2002-05-28 Pfizer Inc Heterocyclic ring-fused pyrimidine derivatives
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
TR199900048T2 (xx) 1996-07-13 1999-04-21 Glaxo Group Limited Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler
DE69730607T2 (de) 1996-07-19 2005-01-27 Takeda Chemical Industries, Ltd. Fas ligand ähnliches protein, seine herstellung und verwendung
CN1237177A (zh) 1996-11-27 1999-12-01 辉瑞大药厂 稠合的二环嘧啶衍生物
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
PE20011178A1 (es) 2000-04-07 2001-11-19 Takeda Chemical Industries Ltd Compuestos heterociclicos y su produccion
NZ522568A (en) 2000-06-22 2004-12-24 Pfizer Prod Inc Substituted bicyclic derivatives for the treatment of abnormal cell growth
CN1211382C (zh) 2000-06-30 2005-07-20 葛兰素集团有限公司 喹唑啉二甲苯磺酸盐化合物
US6984653B2 (en) * 2001-10-05 2006-01-10 Takeda Pharmaceutical Company Limited Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof
JP4202926B2 (ja) 2001-12-12 2008-12-24 ファイザー・プロダクツ・インク Ｅ−２−メトキシ−ｎ−（３−（４−（３−メチル−ピリジン−３−イロキシ）−フェニルアミノ）−キナゾリン−６−イル）−アリル）−アセトアミドの塩形態、その製造および癌に対するその使用
AU2002339687A1 (en) 2001-12-12 2003-06-23 Pfizer Products Inc. Quinazoline derivatives for the treatement of abnormal cell growth
AU2002357193A1 (en) 2001-12-19 2003-07-09 Smithkline Beecham Corporation Thienopyrimidine compounds as protein tyrosine kinase inhibitors
ATE478872T1 (de) 2002-03-28 2010-09-15 Ustav Ex Botan Av Cr V V I I O Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung
MEP8409A (en) 2004-06-02 2011-12-20 Fused heterocyclic compound
TW200730527A (en) * 2005-12-02 2007-08-16 Takeda Pharmaceuticals Co Fused heterocyclic compound

Also Published As

Publication number Publication date
BRPI0720169A2 (pt) 2013-12-24
TW200925160A (en) 2009-06-16
US20100004238A1 (en) 2010-01-07
CA2673097A1 (en) 2008-06-19
PE20091243A1 (es) 2009-09-07
AR066962A1 (es) 2009-09-23
EP2103620A1 (en) 2009-09-23
KR20090090336A (ko) 2009-08-25
JPWO2008072634A1 (ja) 2010-04-02
CN101611041A (zh) 2009-12-23
RU2009126576A (ru) 2011-01-20
WO2008072634A1 (ja) 2008-06-19

Similar Documents

Publication Publication Date Title
MX2009006315A (es) Compuesto heterociclico fusionado.
TW200611907A (en) Fused heterocyclic compound
ES2552932T3 (es) Ligandos del receptor nicotínico neuronal de la acetilcolina alfa4beta2
MA32319B1 (fr) Derives de triazine utiles comme inhibiteurs de la kinase pi3 et de mtor
UA81468C2 (en) Heteroarylcarbamoylbenzene derivatives
EP1604665A4 (en) C-KIT KINASE HEMMER
DE502005006204D1 (de) 8- ä3-amino-piperidin-1-ylü-xanthine, deren herstellung und deren verwendung als arzneimittel
NZ579928A (en) Fluorinated derivatives of deferiprone
TW200604184A (en) Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
MY160443A (en) Nitrogen-containing heterocyclic compound and agricultural fungicide
TW200736363A (en) Material for organic electroluminescent device and organic electroluminescent device
MX2010009416A (es) Compuestos heterociclicos como inhibidores de cxcr2.
TN2010000091A1 (en) Substituted pyrazole derivative
MXPA03005119A (es) Activadores de glucoquinasa heteroaromaticos fusionados.
TNSN08372A1 (en) Heterocyclic amides for use as pharmaceuticals
WO2009057784A1 (ja) 複素環化合物
ATE453639T1 (de) Phenylsubstituierte pyrimidinverbindungen zur verwendung als kinasehemmer
MX2009010824A (es) Compuesto de hidrazida heterociclica y uso pesticida del mismo.
MX2010006202A (es) Derivados de oxindol substituidos por amidometil y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
MY146491A (en) Fused pyrrole derivatives
JO3259B1 (ar) مشتق دائري مغاير ملتحم واستخدامه
TW200700396A (en) Pyrazine-2-carboxamide derivatives as mglur5 antagonists
TW200619206A (en) Chemokine-binding heterocyclic compound salts, and methods of use thereof
MX2009010823A (es) Compuesto de hidrazida y agente controlador de artropodos dañinos que contiene el mismo.
WO2009018065A3 (en) Novel glucokinase activators and methods of using same